ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) P/E ratio
As of 25 September 2026, ResMed Inc. (RMD) trades at a P/E ratio of 21.3×. Over the past ten years it has ranged from 17.6× (June 2026) to 90.9× (September 2021); the current reading is higher than 4% of that period. That is below the Medical Instruments & Supplies industry median of 34.2× and below the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 18.6× | (31.04%) |
| FY2025 | 27.0× | 0.29% |
| FY2024 | 26.9× | (24.68%) |
| FY2023 | 35.8× | (9.07%) |
| FY2022 | 39.3× | (47.83%) |
| FY2021 | 75.4× | 69.23% |
| FY2020 | 44.5× | 1.87% |
| FY2019 | 43.7× | (6.45%) |
| FY2018 | 46.7× | 45.28% |
| FY2017 | 32.2× | 24.17% |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 18.6× | (13.68%) |
| Mar 2026 | 21.6× | (9.04%) |
| Dec 2025 | 23.7× | (14.95%) |
| Sep 2025 | 27.9× | 3.29% |
| 42 more quarters | Free account |
Against its own ten years
Low 17.6×
High 90.9×
Ten-year median
32.7×
Current reading's percentile
4
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BAX Baxter International Inc. compare | n/m |
| SOLV Solventum Corporation compare | 10.9× |
| COO The Cooper Companies, Inc. compare | 18.9× |
| RMD ResMed Inc. | 21.3× |
| WST West Pharmaceutical Services, Inc. compare | 47.1× |
| ALC Alcon compare | 49.2× |
| BDX Becton, Dickinson and Company compare | 55.4× |
| RGEN Repligen Corporation compare | 253× |
| MDLN Medline Inc. compare | — |
| Medical Instruments & Supplies industry median | 34.2× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement